The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review
Open Access
- 3 October 2019
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 146 (6) , 1479-1489
Abstract
Patients with melanoma brain metastases (MBM) still have a very poor prognosis. Several treatment modalities have been investigated in an attempt to improve the management of MBM. This review aimed to evaluate the impact of current treatments for MBM on patient‐ and tumor‐related outcomes, and to provide treatment recommendations for this patient population. A literature search in the databases PubMed, Embase, Web of Science and Cochrane was conducted up to January 8, 2019. Original articles published since 2010 describing patient‐ and tumor‐related outcomes of adult MBM patients treated with clearly defined systemic therapy were included. Information on basic trial demographics, treatment under investigation and outcomes (overall and progression‐free survival, local and distant control and toxicity) were extracted. We identified 96 eligible articles, comprising 95 studies. A large variety of treatment options for MBM were investigated, either used alone or as combined modality therapy. Combined modality therapy was investigated in 71% of the studies and resulted in increased survival and better distant/local control than monotherapy, especially with targeted therapy or immunotherapy. However, neurotoxic side‐effects also occurred more frequently. Timing appeared to be an important determinant, with the best results when radiotherapy was given before or during systemic therapy. Improved tumor control and prolonged survival can be achieved by combining radiotherapy with immunotherapy or targeted therapy. However, more randomized controlled trials or prospective studies are warranted to generate proper evidence that can be used to change the standard of care for patients with MBM.Keywords
This publication has 119 references indexed in Scilit:
- Surgical management of melanoma brain metastases in patients treated with immunotherapyJournal of Neurosurgery, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Prognostic factors for survival in melanoma patients with brain metastasesCancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Determinants of survival in patients with brain metastases from cutaneous melanomaBritish Journal of Cancer, 2010
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II studyAnnals of Oncology, 2009
- Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical featuresNeuro-Oncology, 2008
- Determinants of Outcome in Melanoma Patients With Cerebral MetastasesJournal of Clinical Oncology, 2004
- Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanomaJournal of Neurosurgery, 1998